Cargando…
Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity
Serogroup B meningococcus (MenB) is a leading cause of meningitis and sepsis across the world and vaccination is the most effective way to protect against this disease. 4CMenB is a multi-component vaccine against MenB, which is now licensed for use in subjects >2 months of age in several countrie...
Autores principales: | Bartolini, E., Borgogni, E., Bruttini, M., Muzzi, A., Giuliani, M., Iozzi, S., Petracca, R., Martinelli, M., Bonacci, S., Marchi, S., Brettoni, C., Donati, C., Torricelli, G., Guidotti, S., Domina, M., Beninati, C., Teti, G., Felici, F., Rappuoli, R., Castellino, F., Del Giudice, G., Masignani, V., Pizza, M., Maione, D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536418/ https://www.ncbi.nlm.nih.gov/pubmed/33020485 http://dx.doi.org/10.1038/s41467-020-18791-0 |
Ejemplares similares
-
Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect
por: Ruiz García, Yara, et al.
Publicado: (2021) -
4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp
por: Veggi, Daniele, et al.
Publicado: (2020) -
OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans
por: Viviani, Viola, et al.
Publicado: (2023) -
Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland
por: Bodini, Margherita, et al.
Publicado: (2020) -
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal
por: Simões, Maria João, et al.
Publicado: (2017)